According to Reuters, Robert Bradway, CEO of Amgen, said on Wednesday that the company will test its candidate weight loss drug in patients at risk of weight-related diseases such as heart, liver, and kidney. Bradway said at the Morgan Stanley healthcare conference that MariTide has a different mechanism of action and a lower dosing frequency compared to Lilly's Zepbound and Novo Nordisk's Wegovy, making it the next generation of weight loss drugs.
安进拟在患有心脏、肝脏和肾脏等疾病的患者中测试候选减肥药
Amgen plans to test the candidate weight loss drug in patients with heart, liver, and kidney diseases.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated